Stoke Therapeutics, Inc. (STOK) Operating Margin
- Operating margin · 12 months: Value -809.69%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -809.69% | Operating income / revenue. Period ending 2026-06-30. $-223.38M ÷ $27.59M × 100 ≈ -809.69% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -223.38M USD | Operating Income (Loss) |
| Revenue | 27.59M USD | |
| Cost of products and services | (m) | |
| Research and development | 168.56M USD | Research and Development Expense |
| Selling, general and administration | 82.40M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-223.38M | $27.59M | (m) | $168.56M | $82.40M | -809.69% |
| 2026-03-31 | $-185.25M | $32.08M | (m) | $144.92M | $72.41M | -577.46% |
| 2025-12-31 | $-20.59M | $184.42M | (m) | $137.92M | $67.09M | -11.16% |
| 2025-09-30 | $27.20M | $205.63M | (m) | $119.65M | (m) | 13.23% |
| 2025-06-30 | $40.28M | $199.89M | (m) | $104.16M | (m) | 20.15% |
| 2025-03-31 | $38.24M | $190.91M | (m) | $99.44M | (m) | 20.03% |
| 2024-12-31 | $-101.37M | $36.55M | (m) | $89.13M | (m) | -277.31% |
| 2024-09-30 | $-117.31M | $16.74M | (m) | $87.49M | (m) | -700.62% |
| 2024-06-30 | $-114.53M | $15.16M | (m) | $85.55M | (m) | -755.65% |
| 2024-03-31 | $-118.45M | $7.84M | (m) | $84.97M | (m) | -1510.14% |
| 2023-12-31 | $-114.77M | $8.78M | (m) | $82.23M | (m) | -1307.21% |
| 2023-09-30 | $-112.36M | $9.25M | (m) | $81.51M | (m) | -1215.26% |
| 2023-06-30 | $-112.28M | $8.84M | (m) | $81.35M | (m) | -1269.53% |
| 2023-03-31 | $-104.25M | $14.56M | (m) | $79.16M | (m) | -716.16% |
| 2022-12-31 | $-104.36M | $12.40M | (m) | $77.84M | (m) | -841.24% |
| 2022-09-30 | $-101.71M | (m) | (m) | $72.58M | (m) | (m) |
| 2022-06-30 | $-97.24M | (m) | (m) | $66.83M | (m) | (m) |
| 2022-03-31 | $-94.03M | (m) | (m) | $62.56M | (m) | (m) |
| 2021-12-31 | $-86.06M | (m) | (m) | $54.17M | (m) | (m) |
| 2021-09-30 | $-76.13M | (m) | (m) | $47.27M | (m) | (m) |
| 2021-06-30 | $-67.15M | (m) | (m) | $41.02M | (m) | (m) |
| 2021-03-31 | $-58.14M | (m) | (m) | $34.90M | (m) | (m) |
| 2020-12-31 | $-53.04M | (m) | (m) | $32.20M | (m) | (m) |
| 2020-09-30 | $-49.53M | (m) | (m) | $30.38M | (m) | (m) |
| 2020-06-30 | $-45.66M | (m) | (m) | $28.79M | (m) | (m) |
| 2020-03-31 | $-41.09M | (m) | (m) | $26.85M | (m) | (m) |
| 2019-12-31 | $-35.68M | (m) | (m) | $23.76M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-17.19M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-12.78M | (m) | (m) | $8.37M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |